International Stem Cell (ISCO) EBIT (QoQ) (2010 - 2025)
International Stem Cell (ISCO) EBIT (QoQ) (2010 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -432.98% |
| Sep 30, 2025 | -43.71% |
| Jun 30, 2025 | 177.67% |
| Mar 31, 2025 | -521.57% |
| Dec 31, 2024 | 156.67% |
| Sep 30, 2024 | -160.40% |
| Jun 30, 2024 | 183.71% |
| Mar 31, 2024 | 58.02% |
| Dec 31, 2023 | -337.11% |
| Sep 30, 2023 | 32.64% |
| Jun 30, 2023 | -7,300.00% |
| Mar 31, 2023 | -96.72% |
| Dec 31, 2022 | 120.33% |
| Sep 30, 2022 | -1,067.74% |
| Jun 30, 2022 | 24.00% |
| Mar 31, 2022 | 107.74% |
| Dec 31, 2021 | 48.15% |
| Sep 30, 2021 | -53.45% |
| Jun 30, 2021 | 28.40% |
| Mar 31, 2021 | 22.65% |